NSE · Healthcare · Drug Manufacturers - Specialty & Generic
| Holder | Stake |
|---|---|
| Manish Gupta | 3.08% |
| Investor Education and Protection Fund Authority Ministry of Corporate Affairs | 1.49% |
| Authum Investment and Infrastructure | 1.47% |
| Sanjiv Kumar Dudeja | 1.41% |
| Lincoln P Coelho | 1.18% |
| Document | Date |
|---|---|
| Annual report FY2026 JAGSONPAL PHARMACEUTICALS LIMITED - FY2025-26 SUMMARY HEADLINE NUMBERS • Revenue from operations: ₹2,872 mn (6.9% YoY growth) • Operating EBITDA: ₹6 | 2026-08-27 |
| Q1 FY27 earnings call JAGSONPAL PHARMACEUTICALS LIMITED – Q1 FY27 EARNINGS SUMMARY HEADLINE NUMBERS • Revenue from operations: Rs.82 crores, up 9% year-on-year • Gross pr | 2026-08-04 |
| Q4 FY26 earnings call JAGSONPAL PHARMACEUTICALS LIMITED – Q4 FY26 SUMMARY HEADLINE NUMBERS • FY26 Revenue: INR287 crores, growth of 7% year-on-year • Q4 FY26 Revenue: INR | 2026-05-04 |
| Quarterly results · Q4 FY26 JAGSONPAL PHARMACEUTICALS LIMITED – FY26 RESULTS SUMMARY HEADLINE NUMBERS • Revenue FY26: ₹2,872 Mn (up 6.9% YoY); Q4FY26: ₹642 Mn (up 9.6% YoY) • O | 2026-04-27 |
| Investor presentation · Q4 FY26 JAGSONPAL PHARMACEUTICALS LIMITED – FY26 RESULTS SUMMARY HEADLINE NUMBERS • Revenue FY26: ₹2,872 Mn, up 6.9% YoY (₹2,687 Mn in FY25) • Q4FY26 Revenu | 2026-04-27 |
| Q3 FY26 earnings call JAGSONPAL PHARMACEUTICALS LIMITED – Q3 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q3 FY26 revenue: INR 73 crores (essentially flat year-on-year, -1% g | 2026-01-27 |
| Investor presentation · Q3 FY26 JAGSONPAL PHARMACEUTICALS LIMITED – Q3 & 9MFY26 FINANCIAL SUMMARY HEADLINE NUMBERS • 9-Month Revenue (9MFY26): ₹2,230 Mn, up 6% YoY from ₹2,102 Mn i | 2026-01-21 |
| Quarterly results · Q3 FY26 JAGSONPAL PHARMACEUTICALS LIMITED - FINANCIAL SUMMARY Q3 & 9-Month Results (December 31, 2025) --- HEADLINE NUMBERS • Q3 FY2026 Revenue from Operat | 2026-01-21 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹4 / share ex-date Sep 4, 2026 | 2026-09-04 |
| Dividend | ₹2.50 / share ex-date Sep 12, 2025 | 2025-09-12 |
| Announcement | Date |
|---|---|
| Acquisition of wellness portfolio from group pharmaceuticals Jagsonpal Pharmaceuticals Limited acquired the Wellness Portfolio from Group Pharmaceuticals Limited through a business transfer agreement on September 23, 2026. The portfolio generated ₹24. | 2026-09-23 |
| Acquisition of Wellness Portfolio from Group Pharmaceuticals Limited Jagsonpal Pharmaceuticals Limited has agreed to acquire the Wellness Portfolio of Group Pharmaceuticals Limited through a Business Transfer Agreement signed on September 23, 2026. This is a | 2026-09-23 |
| Updates on acquisition of Aequitas Healthcare Private Limited Jagsonpal Pharmaceuticals Limited announced an acquisition of Aequitas Healthcare Private Limited. This is a strategic move to expand the company's business portfolio and market presence. Ac | 2026-07-17 |
| Acquisition of Aequitas Healthcare Private Limited Jagsonpal Pharmaceuticals Limited announced an update regarding its acquisition of Aequitas Healthcare Private Limited. This acquisition represents a strategic expansion move for the company | 2026-07-08 |
| Acquisition of Aequitas Healthcare Private Limited Jagsonpal Pharmaceuticals Limited announced an acquisition of Aequitas Healthcare Private Limited. This strategic move represents the company's expansion into new business areas or markets. | 2026-07-07 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Jagsonpal Pharmaceuticals Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.